Tidal ETF Trust II YieldMax AMZN Option Income Strategy ETF (ARCA: AMZY)

Latest news for Tidal ETF Trust II YieldMax AMZN Option Income Strategy ETF (ARCA:AMZY)

The Fund is an actively managed exchange-traded fund (ETF) that seeks current income while maintaining the opportunity for exposure to the share price (i.e., the price returns) of the common stock of Amazon.com, Inc. (AMZN), subject to a limit on potential investment gains. The Fund will seek to employ its investment strategy as it relates to AMZN regardless of whether there are periods adverse market, economic, or other conditions and will not seek to take temporary defensive positions during such periods.

First American Government Obligations Fund

YieldMax AMZN Option Income Strategy ETF

Tidal ETF Trust II YieldMax AMZN Option Income Strategy ETF

WIIM

SLXN

Silexion Therapeutics shares are trading higher after the company announced Guangzhou Sino-Israel bio-industry investment fund reported a 13.8% stake in the company.

Barclays analyst Saket Kalia maintains Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) with a Overweight and raises the price target from $42 to $51.

News

Price Target

Analyst Ratings

RBRK

Barclays Maintains Overweight on Rubrik, Raises Price Target to $51

LuxUrban Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.01) by 2300 percent. This is a 318.18 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $13.13 million which missed the analyst consensus estimate of $28.05 million by 53.18 percent. This is a 57.92 percent decrease over sales of $31.21 million the same period last year.

Earnings

LUXH

LuxUrban Hotels Q3 EPS $(0.24) Misses $(0.01) Estimate, Sales $13.13M Miss $28.05M Estimate

Events

CGON

CG Oncology To Present At Society of Urologic Oncology (SUO) 25th Annual Meeting Dec. 4-6

Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) will discuss its strategic priorities and long-term financial commitments with the investment community today at <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42084062/delta-highlights-differentiation-durability-at-2024-investor-day" rel="noreferrer noopener">2024 Investor Day in New York.</a>
&#8220;We are introducing a three-to-five-year financial framework across key value drivers including margin expansion, durable earnings and free cash flow, and balance sheet strength that reflect Delta&#8217;s financial discipline and strategic priorities,&#8221; commented Delta CFO Dan Janki.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/travel/24/11/42014787/delta-united-alaska-air-are-top-analyst-picks-in-airline-sector" rel="noreferrer noopener">Delta, United, Alaska Air Are Top Analyst Picks In Airline Sector</a>
Delta&#8217;s three-to-five-year financial framework targets mid-teens operating margins, 10% average annual EPS growth, and $3-5 billion in annual free cash flow. With 1x gross leverage, 15%+ return on invested capital, and $40 billion in unencumbered assets, the framework emphasizes margin expansion, durable earnings, and balance sheet strength.
Delta&nbsp;also reaffirmed its expected <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41270201/deltas-turbulent-q3-mixed-results-and-tech-troubles-cloud-holiday-outlook" rel="noreferrer noopener">fourth-quarter financial guidance</a>. On a non-GAAP basis, the company expects revenue growth of 2% – 4%, EPS of $1.60 – $1.85 versus $1.74 consensus, and an operating margin of 11% &#8211; 13%.
The company also provided preliminary commentary on 2025 for capacity growth of three to four percent year-over-year, revenue growth of mid-single digits and non-fuel unit cost growth of low-single digits year-over-year.&nbsp;
Price Action: DAL shares are trading higher by 0.39% at $65.00 premarket at the last check Wednesday.
Photo via Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42076876/what-could-trumps-new-dot-pick-mean-for-evs-airlines-railroads" target="_blank" rel="noreferrer noopener">What Trump&#8217;s DOT Pick Could Mean For EVs, Airlines, Railroad Stocks</a></li>
</ul>

Equities

Guidance

Delta Charts Path To High Margins And Shareholder Gains At 2024 Investor Day

Quantum-Si shares are trading higher after the company announced a distribution agreement with Avantor for next-generation protein sequencing portfolios for researchers.

Raymond James analyst Danielle Brill initiates coverage on Tectonic Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) with a Outperform rating and announces Price Target of $65.

Initiation

TECX

Raymond James Initiates Coverage On Tectonic Therapeutic with Outperform Rating, Announces Price Target of $65

-Strategic initiative would provide LuxUrban with a $7 million initial capital infusion, offering the opportunity to broaden its market impact representing a key milestone in building Lux 2.0
-Joint venture would leverage advanced technology integration to streamline operations, elevate service offerings, and deliver an enhanced guest experience
MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- LuxUrban Hotels Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>), a hospitality company that leases entire hotels on a long-term basis, manages these hotels, and rents out rooms to guests in the properties it leases, today announced the signing of a Non-Binding Letter of Intent (LOI) with Lockwood Development Partners LLC and The Bright Hospitality Management, LLC proposing to establish a joint venture ("JV") focused on hotel services and operations.
The joint venture would initially focus on two LuxUrban properties in New York City, with the parties to consider expansion of the relationship to include additional LuxUrban hotels based on the success of the initiative. The collaboration would leverage Lockwood's established presence in hotel development and Bright's innovative hospitality technology to create a unique guest experience and optimize operational efficiencies.
Key Highlights of the Joint Venture:
Initial Capital Investment: Lockwood would initially invest approximately $7 million to address obligations and enhance facilities in the initial two JV hotels, with potential additional investments reaching up to $35 million if all existing LuxUrban hotels are later added to the JV structure.

Contracts

LuxUrban Hotels Signs A Non-Binding LOI For Proposed Joint Venture With Lockwood Development Partners LLC And The Bright Hospitality Management To Elevate Hotel Operations And Guest Experience; Strategic Initiative Would Provide LuxUrban With A $7M Initial Capital Infusion, Offering The Opportunity To Broaden Its Market Impact Representing A Key Milestone In Building Lux 2.0

Wix.com shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 revenue guidance. Also, multiple firms raised their respective price targets on the stock.

Genius Group Sees Prelim. 1H Revenue $13.2M vs $11.8M YoY; Sees Prelim. 1H Pro Forma Revenue $20.7M vs $9M YoY

Barclays analyst Tim Long maintains Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) with a Overweight and raises the price target from $180 to $200.

KEYS

Barclays Maintains Overweight on Keysight Techs, Raises Price Target to $200

DUOT

Duos Technologies Secures $42M Asset Management Deal With Fortress To Oversee 850MW Mobile Gas Turbine Portfolio, Targeting Deployment For U.S. Data Centers And Global Power Projects

Pivotal Research analyst Jeffrey Wlodarczak maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Buy and raises the price target from $925 to $1100.

NFLX

Pivotal Research Maintains Buy on Netflix, Raises Price Target to $1100

Dynatrace integrates with Microsoft security technology to enhance cloud security for customers
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dynatrace.com%2F&amp;esheet=54155433&amp;newsitemid=20241120414876&amp;lan=en-US&amp;anchor=Dynatrace&amp;index=1&amp;md5=d6e91ac491e18743dbdd4bb3bfbcb642">Dynatrace</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) has become a member of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Faka.ms%2FMISA&amp;esheet=54155433&amp;newsitemid=20241120414876&amp;lan=en-US&amp;anchor=Microsoft+Intelligent+Security+Association+%28MISA%29&amp;index=2&amp;md5=63446b9c4e4e83e7483fff7e054d85a7">Microsoft Intelligent Security Association (MISA)</a> to provide customers with enhanced cloud security solutions through continuous innovation and collaboration with Microsoft and other MISA members. MISA is an ecosystem of independent software vendors (ISVs) and managed security service providers (MSSPs) that have integrated their solutions with Microsoft security technology to better defend mutual customers against cyber threats, which are rapidly increasing. According to recent Dynatrace research, nearly <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dynatrace.com%2Finfo%2Freports%2Fciso-report-state-of-application-security%2F&amp;esheet=54155433&amp;newsitemid=20241120414876&amp;lan=en-US&amp;anchor=72%25+of+CISOs+have+faced+application+security+incidents+in+the+past+two+years&amp;index=3&amp;md5=e6d21a2b776a415778f4648c77b9f5c4">72% of CISOs have faced application security incidents in the past two years</a>.
Dynatrace was nominated to MISA because of its powerful integration with Microsoft's SIEM solution, Microsoft Sentinel. Dynatrace delivers comprehensive observability and security, offering vital insights that simplify cloud complexity and empower organizations to proactively combat evolving cyber threats. By merging the insights from Dynatrace with Microsoft Sentinel, organizations gain a more holistic understanding of their security posture. As a result, SecOps teams can detect application attack attempts more effectively, streamline incident management, and proactively mitigate issues as part of their efforts to keep their cloud-native environments secure and their business operations resilient.

Dynatrace Integrates With Microsoft Security Technology To Enhance Cloud Security For Customers

Williams-Sonoma shares are trading higher after the company reported better-than-expected Q3 financial results. Also, the company approved a $1 billion stock repurchase authorization.

French biotech company Aelis Farma, specializing in the treatment of brain disorders announced positive results Monday from a <a href="https://www.benzinga.com/markets/cannabis/22/11/29769327/aelis-farmas-drug-candidate-for-the-treatment-of-cognitive-disorders-authorized-for-the-first-tr">Phase 1/2 trial of its drug candidate AEF0217</a> in young adults with Down syndrome. The study, conducted in Spain, assessed the safety, tolerability and potential efficacy of AEF0217, a selective CB1 receptor inhibitor targeting cognitive and behavioral impairments.
The study successfully met its safety (primary), pharmacokinetics (secondary) and efficacy (secondary and exploratory) objectives. AEF0217 was well tolerated and no safety concerns were observed. The drug improved adaptive behavior in areas such as communication, daily living skills and socialization.
"The promising and impressive results of this study generate a real hope to develop an efficacious and safe treatment for the cognitive disabilities of people with Down syndrome," stated Prof. Rafael de la Torre Fornell, the trial's principal investigator. "Particularly striking are the efficacy data, which addresses crucial domains of adaptation, such as expression and writing abilities as well as certain daily living skills and societal interactions. These types of effects, especially because obtained after only four weeks of treatment, are certainly a first in the field of Down syndrome and represent a major step towards the development of a treatment that could significantly improve the autonomy and adaptation of people with Down syndrome. I would like to take this occasion to also send my warmest thanks to the participants, their families and family associations who supported this innovative project and helped us to complete this pioneering clinical trial."
It is noteworthy that AEF0217 seemed to induce larger improvements in participants with the greater impairments before starting the treatment.
Moreover, adaptive behavior and cognition were assessed after just four weeks of treatment, whereas experts generally believe several months are needed to modify these functions in neurodevelopmental disabilities.
Read Also: <a href="http://a/">Can THC Turn Back The Clock? Cannabis Reverses Brain Aging, Boosts Mental Capacity, New Study Suggests</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Paving The Way For Treating Other Cognitive Disorders</h2>
Pier Vincenzo Piazza, CEO of Aelis Farma, concluded, "We see this accomplishment as a milestone in the development of a promising therapy that could significantly improve the autonomy and quality of life of people with Down syndrome. It is also, more generally, the first evidence of the positive impact of AEF0217 on cognition, which could pave the way for the treatment of other cognitive disorders."
Piazza also highlighted that these results offer a supplementary validation of the safety of the new pharmacological class developed by the company &#8211; Signaling Specific inhibitors of the CB1 receptor (CB1-Ssi). "We believe that the CB1-SSi represent a major innovation in pharmacology that will allow to generate inhibitors not only efficacious but also safe and well tolerated, opening the way to new treatments of conditions without treatment today," he concluded.
Following these results, Aelis Farma plans a Phase 2 international study in 2025 to further evaluate its efficacy and adaptative behavior improvements.
The clinical development of AEF0217, the phase 1 program in healthy volunteers, the phase 1/2 just completed and the next phase 2 in people with Down syndrome are part of the European H2020 ICOD project (Improving COgnition in Down syndrome, Grant Agreement ID 899986). The ICOD project received €6 million ($6.33 million) of fundings from the European Commission and involves partners in Spain, France and Italy.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40722274/french-biotech-candidate-for-cannabis-use-disorder-fails-phase-2b-clinical-trial-indivior-will-n">French Biotech Candidate For Cannabis Use Disorder Fails Phase 2B Clinical Trial, Indivior Will Not Exercise Option</a>
Photo generated with AI

Cannabis

After Four Weeks, New Drug Shows Promising Results In Boosting Life Skills For Down Syndrome Patients

Barclays analyst David Anderson maintains Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) with a Equal-Weight and lowers the price target from $39 to $36.

Barclays Maintains Equal-Weight on Helmerich & Payne, Lowers Price Target to $36

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.revvity.com%2F&amp;esheet=54154236&amp;newsitemid=20241120885442&amp;lan=en-US&amp;anchor=Revvity%2C+Inc.&amp;index=1&amp;md5=734f9e2528f29d1743f3737836d014d9">Revvity, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>), today announced an expansion of its work with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.genomicsengland.co.uk%2F&amp;esheet=54154236&amp;newsitemid=20241120885442&amp;lan=en-US&amp;anchor=Genomics+England&amp;index=2&amp;md5=62309642013e7279670dbdec9857db39">Genomics England</a> that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties' long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England's renowned research programs, supporting diverse areas in genomics, and fostering talent in innovative healthcare fields.
A cornerstone of the collaboration is the Generation Study, a world-leading study led by Genomics England, in partnership with the National Health Service, that aims to screen up to 100,000 newborns for 200 rare genetic conditions in England. In the study, which launched earlier this year, Revvity's Omics laboratory in Manchester, UK will work with Genomics England to advance the early detection of genetic conditions in newborns. Utilizing the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.revvity.com%2Fproduct%2Fchemagic-360-2024-0020&amp;esheet=54154236&amp;newsitemid=20241120885442&amp;lan=en-US&amp;anchor=chemagic+360%26%238482%3B+instrument&amp;index=3&amp;md5=cc70a716c8b70a1640ca92c2df8d17aa">chemagic 360&#x2122; instrument</a>, Revvity's team will extract DNA from cord blood samples collected from newborns across England.

Biotech

General

RVTY

Revvity Announces An Expansion Of Its Work With Genomics England That Leverages Both Organizations' Expertise And Resources To Advance Critical Genomic Initiatives Across The United Kingdom

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $8 price target.

Reiteration

GOVX

HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target

Piper Sandler analyst James Callahan initiates coverage on AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Overweight rating and announces Price Target of $400.

Piper Sandler Initiates Coverage On AppLovin with Overweight Rating, Announces Price Target of $400

AMZY Provides Investors With Similar Exposure To AMZN With Income In Mind

The benefit of covered call trading is the nice monthly cash income no matter whether the underlying stocks are going up, down, or sideways.

Unlock High Yields With Covered-Call ETFs

84 Monthly Paid Dividend Stocks And 80 Funds For September

AMZY: Extract A 40% Distribution From Amazon

AMZY: Multiple Ways To Utilize This Fund

Steady Cash Flow Meets Tech Titans: A Look At YMAG

YieldMax™ AMZN Option Income Strategy ETF declares $0.7632 dividend

72 Monthly Paid Dividend Stocks And 80 Funds For October

AMZY: Chasing The 50% Yield: Is It Worth The Risk?

AGNC

AMZN

AMZP

AMZY

APLY

BDORY

CLSPF

CNDCF

CRSH

DISO

EARN

FIAT

FNNCF

GIPR

GLAD

GOOY

HRZN

ICRP

JPMO

MAXI

MSFO

NVDY

OXSQ

PEYUF

PFLT

PSEC

PYPY

SQQQ

TQQQ

TSLY

TTBKF

TUERF

USOY

YBIT

YBTC

YMAG

YMAX

Comments

Tidal ETF Trust II YieldMax AMZN Option Income Strategy ETF

News

Latest news for Tidal ETF Trust II YieldMax AMZN Option Income Strategy ETF (ARCA:AMZY)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga